The article supports the idea of providing infrastructure and training for preparing and publishing quality video articles. Properly edited, formatted, and verified video items can present graphic contents of interest to the global scientific community. It is suggested to apply traditional attributes of scholarly articles to video items and aggregate them on a specifically designed editing, publishing, and indexing platform, called PubTube. As a mega platform, PubTube may provide space for a variety of open-access sources of information, ranging from short audio-video presentations to research protocols and educational lectures. Video articles on the platform have to pass quality checks by skilled reviewers. Global editorial associations should be prepared to improving the whole process of publishing and aggregating video articles.
Editorial Policies ; Information Dissemination/*methods ; Internet/*organization & administration ; *Multimedia ; Peer Review, Research/*methods ; Publishing

Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for high-grade neoplasms. So, researchers seek methods to improve therapeutic index as a critical aim of treatment. One of these new challenging methods is radioimmunotherapy (RIT) that involves recruiting a coupling of radionuclide component with monoclonal antibody (mAb) which are targeted against cell surface tumor–related antigens or antigens of cells within the tumor microenvironment. In the context of cancer care, precision medicine is exemplified by RIT; precision medicine can offer a tailored treatment to meet the needs for treatment of brain tumors. This review aims to discuss the molecular targets used in radioimmunotherapy of brain tumors, available and future radioimmunopharmaceutics, clinical trials of radioimmunotherapy in brain neoplasms, and eventually, conclusion and future perspective of application of radioimmunotherapy in neurooncology cancer care.
Brain Neoplasms ; Brain ; Humans ; Incidence ; Precision Medicine ; Prognosis ; Radioimmunotherapy ; Tumor Microenvironment

Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for high-grade neoplasms. So, researchers seek methods to improve therapeutic index as a critical aim of treatment. One of these new challenging methods is radioimmunotherapy (RIT) that involves recruiting a coupling of radionuclide component with monoclonal antibody (mAb) which are targeted against cell surface tumor–related antigens or antigens of cells within the tumor microenvironment. In the context of cancer care, precision medicine is exemplified by RIT; precision medicine can offer a tailored treatment to meet the needs for treatment of brain tumors. This review aims to discuss the molecular targets used in radioimmunotherapy of brain tumors, available and future radioimmunopharmaceutics, clinical trials of radioimmunotherapy in brain neoplasms, and eventually, conclusion and future perspective of application of radioimmunotherapy in neurooncology cancer care.